CytomX Therapeutics Announces Presentations at 2019 ASCO Annual Meeting

On May 15, 2019 CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody therapeutic technology platform, reported that additional clinical results from PROCLAIM-072, an ongoing Phase 1/2 trial evaluating CX-072, a Probody therapeutic targeting PD-L1, will be presented in a Poster Session and as part of a Poster Discussion Session at the 2019 Annual Meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) (Press release, CytomX Therapeutics, MAY 15, 2019, View Source [SID1234536386]). The conference will take place from May 31 – June 4 in Chicago, Illinois.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster and presentation will detail additional results from the monotherapy expansion arms of the PROCLAIM-CX-072 trial with a data cutoff date of April 5, 2019.

Poster Presentation

Abstract: #2513 / Poster Board: #157

Title: CX-072, a PD-L1 Probody Therapeutic, as Monotherapy in Patients with Advanced Solid Tumors: Preliminary Results of PROCLAIM-CX-072

Presenter: Aung Naing, M.D., FACP, The University of Texas MD Anderson Cancer Center

Session: Developmental Immunotherapy and Tumor Immunobiology

Date/Time: Saturday, June 1, 8:00 – 11:00 a.m.

Location: McCormick Place, Hall A

The accepted abstract is available online on ASCO (Free ASCO Whitepaper)’s website at View Source

Poster Discussion Session

Title: CX-072, a PD-L1 Probody Therapeutic, as Monotherapy in Patients with Advanced Solid Tumors: Preliminary Results of PROCLAIM-CX-072

Presenter: David B. Page, M.D., Providence Cancer Center

Session: Developmental Immunotherapy and Tumor Immunobiology

Date/Time: Saturday, June 1, 1:15 – 2:45 p.m.

Location: McCormick Place, Hall D1

CytomX’s poster will be available online under the Events and Presentations section of the CytomX website at the time of presentation at www.CytomX.com.